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The breast cancer susceptibility protein BRCA2 is essential for recombinational DNA repair. BRCA2
speciﬁcally binds to RAD51 via eight BRC repeat motifs and delivers RAD51 to double-stranded
DNA breaks. In this study, a mammalian two-hybrid assay and competitive ELISA showed that the
interaction between BRC repeat 4 (BRC4) and RAD51 was strengthened by the substitution of a sin-
gle BRC4 amino acid from valine to isoleucine (V1532I). However, the cancer-associated V1532F
mutant exhibited very weak interaction with RAD51. This study used a comparative analysis of
BRC4 between animal species to identify V1532 as an important residue that interacts with RAD51.
Structured summary of protein interactions:
cRAD51 physically interacts with cRAD51 by two hybrid (View interaction)
fBRC4 physically interacts with cRAD51 by two hybrid (View interaction)
cBRC4 physically interacts with cRAD51 by two hybrid (View interaction)
hBRC4 physically interacts with hBRC4 and hRAD51 by competition binding (View Interaction 1, 2)
hBRC4 physically interacts with cRAD51 by two hybrid (View interaction)
hBRC4 binds to hRAD51 by enzyme linked immunosorbent assay (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mutations in the breast cancer susceptibility gene BRCA2 are
associated with a predisposition to breast and ovarian cancers
[1,2]. The product of this gene, BRCA2 protein, is required for the
homologous recombinational repair of DNA double-strand breaks
(DSBs) [3,4]. Furthermore, it has been shown to associate with
RAD51 recombinase, which is conserved from yeasts to mammals
[5,6]. A primary outcome of BRCA2 deﬁciency is chromosomal
instability, which results from a deﬁciency in the repair of DNA
lesions by homologous recombination [7]. The direct interaction
of BRCA2 with RAD51 is mediated by eight highly conserved motifs
called BRC repeats that are positioned in exon 11 in human BRCA2chemical Societies. Published by E
Morimatsu).[8,9]. A previous study determined the three-dimensional crystal
structure of the human RAD51 (hRAD51)–BRC repeat 4 (BRC4)
complex and revealed that the BRC repeats form the binding sur-
face with RAD51 [10].
In female dogs, mammary tumors are the most frequent type of
neoplasm [11,12]. It was recently reported that mammary tumor
development in dogs is associated with BRCA2 [13]. The cloning
of canine BRCA2 and RAD51 [14] facilitated the discovery of the
interaction between BRC repeats and the C-terminus of canine
BRCA2 and RAD51 [15–17]. Surprisingly, subsequent studies show
that canine and feline BRC4 exhibit stronger interactions with
RAD51 than human BRC4, which exhibits the strongest interaction
among the 8 repeats (Fig. 1A) [18]. Only four canine BRC4 amino
acids differ from human BRC4 (V1532I, K1533E, A1535T, and
D1547E), suggesting that these amino acids could be responsible
for strengthening the interaction with RAD51.lsevier B.V. All rights reserved.
Fig. 1. Interaction between BRC4 and RAD51, and multiple sequence alignment of BRC4. (A) The left panel depicts the positions of the BRC4 sequences: human BRC4 (hBRC4),
canine BRC4 (cBRC4), and feline BRC4 (fBRC4). Sequence alignment of BRC repeats (bold letters indicate amino acids that differ from human BRC4). The two-hybrid constructs
were introduced into HeLa cells to measure their interaction with canine RAD51 (cRAD51). Luciferase activity was measured by using a mammalian cell two-hybrid assay.
DBD: GAL4-DNA-binding domain fusion protein. VP16: VP16 transactivation domain fusion protein. The results are expressed as the mean (SE) (n = 4). All graphs in this
report show luciferase activities on the top right column as 100%. (B) Sequence alignment of consensus motifs of BRC repeats and BRC4 of several mammals and chickens. The
IE residues of BRC4 are boxed.
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1527 and 1545-LFDE-1548 are critical for the interaction with
RAD51 [9,19], the functions of other BRC4 residues have not been
investigated. Structural studies suggest that V1532 plays a role in
the adherence of hBRC4 to RAD51 via hydrophobic contact with
the M210 of RAD51 [10]; however, this has not been demonstrated
by functional assays. Moreover, V1532F, a cancer-associated muta-
tionwith unknown functional implications, was identiﬁed from hu-
man breast cancer patients and recorded in the Breast Cancer
Information Core Database (BIC; http://research.nhgri.nih.gov/bic/
) [20].
In this study, we identiﬁed novel amino acids that inﬂuence the
binding intensity between BRC4 and RAD51 by using a mammalian
two-hybrid assay, competitive ELISA, and irradiation-induced fo-
cus formation of RAD51.
2. Materials and methods
2.1. Cell culture
HeLa (RIKEN Cell Bank) and COS-7 (American Type Culture Col-
lection) cell lines were maintained in the presence of 5% CO2 in air
at 37 C in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Sigma)
supplemented with 10% fetal calf serum, streptomycin (38 mg L1),
and penicillin (50 000 U L1).
2.2. Mammalian two-hybrid assay and binding interference assay
For the mammalian cell two-hybrid (MTH) assay, the coding
regions of canine BRC4 (cBRC4, GenBank ID: NM_001006653), felineBRC4 (fBRC4, GenBank ID: NM_001009858) [21], human BRC4
(hBRC4, GenBank ID: NM_000059), and canine RAD51 (cRAD51,
GenBank ID: NM_001003043)were cloned into pM and pVP16 plas-
mids (BD Biosciences). Amino acid substitution mutants of BRC4
were constructed using polymerase chain reaction (PCR)mutagene-
sis and subcloned into thepMvector. TheMTHwasperformedas de-
scribed previously [15]. VP16- and DBD-fused cRAD51 constructs
were introduced intoHeLa cellswith the following interference con-
structs: wild-type hBRC4 (hBRC4wt), V1532I mutant (V1532I),
V1532F, and other mutants (T1526A and G1529R) in NLS-pEGFP-
C1 (BD Biosciences).
2.3. Enzyme-linked immunosorbent assay (ELISA)
Competitive ELISA experiments using BRC peptides, which are
reported to disrupt the hRAD51–BRC4 interaction [9], were per-
formed as outlined in Supplementary data.
2.4. 2,4. RAD51 focus assay
The RAD51 focus assay using EGFP-fused BRC4 constructs was
performed as outlined in Supplementary data.
2.5. Crystal structure modeling
We retrieved the crystal structure of the hRAD51–BRC4 com-
plex from the Research Collaboratory for Structural Bioinformatics
Protein Data Bank at http://www.rcsb.org/ (PDB ID: 1N0W) and
analyzed it using the University of California, San Francisco (UCSF)
Chimera software (http://www.cgl.ucsf.edu/chimera/) [22].
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3.1. Structure-based analysis of BRC4 and comparative analysis of the
interaction between the BRC4 of 3 species and RAD51
Alignment of the BRC4 of several mammals and chicken
revealed that residues 1532-IE-1533 were conserved speciﬁcally
in the order Carnivora [8] (Fig. 1B). Feline and canine BRC4 have
3 and 4 amino acid residues that differ from hBRC4, respectively.
Assessing the interaction between these three BRC4 and RAD51
varieties by using MTH revealed that cBRC4 and fBRC4 exhibited
stronger associations with cRAD51 than hBRC4 (Fig. 1A).
3.2. Mutation analysis of the interaction between BRC4 and RAD51
To identify the key residue to determine the differences in
binding intensity, substitution mutants of canine and feline
BRC4, which mimic human BRC4, were constructed by PCR-ori-
ented mutagenesis; the substituted residues are shown in
Fig. 2A. Luciferase activity was lower in hBRC4 than in cBRC4 or
fBRC4 mutants (Fig. 2A right). A reciprocal analysis was con-
ducted by substituting each of the 4 residues that differed be-
tween human and canine BRC4, namely V1532I, K1533E,
A1535T, and D1547E (Fig. 2B). The V1532I substitution increased
the luciferase activity by approximately ﬁve times (Fig. 2B), while
the other substitutions did not affect the interaction. Immuno-
blots analyzing the protein expression levels of the hBRC4 and
V1532I fusion proteins showed similar expression levels in trans-
fected cells (Fig. 2B).Fig. 2. Effect of amino acid substitutions in BRC4 on its interaction with RAD51. (A) The le
human BRC4 (cBRC4m) and from feline to human BRC4 (fBRC4m). (B) The left panel depic
The GAL4-DNA binding domain fusion proteins of hBRC4wt or V1532I were transiently
anti-GAL4-DBD and peroxidase-labeled secondary antibodies: lane 1, intact cell lysate;3.3. The hBRC4 cancer-associated mutation V1532F affects the
interaction with RAD51
To examine the inﬂuence of the residue substitution from 1532
Val to Phe isolated from individuals with breast cancer, the interac-
tion between hBRC4 mutants and cRAD51 was compared using
MTH. The interaction between V1532F mutant and cRAD51 was
as weak as those with T1526A and G1529R, for which functional
deﬁciencies are reported (Fig. 3A) [23]. To verify the results of the
functional assay, the mutation tool in the UCSF Chimera software
package was used to analyze the possible structural outcomes of
these substitutions (Fig. 3B). The Rotamers tool allows amino acid
side chain rotamers to be viewed and evaluated [22]. The best rota-
mers of Val, Ile, or Phe were selected according to their side-chain
torsion as well as probability values in the rotamer library and in
the context of the structural environment (Fig. 3C). These calcula-
tions revealed that the substitution of V1532I increased the number
of contacts for all kinds of direct interactions, whereas V1532F in-
creased clashes (unfavorable interactions where atoms are too
close together). V1532 showed two contacts with M210 of hRAD51
and no clashes, while I1532 showed ﬁve contacts with A190 and
M210 of RAD51 and no clashes. One the other hand, F1532 showed
ﬁve contacts with A190 of RAD51 and many clashes with H1525 or
T1526 of hBRC4 (Fig. 3D–F). Three other substitutions—namely
K1533E, A1535T, and D1547E—hadminor effects on the interaction
because these residues are opposite the RAD51 binding surfaces
(Fig. 3B). The possible structural outcomes of the previously re-
ported substitutions, T1526A and G1529R, demonstrate changes
in the number of contacts in the b-hairpin structure of BRC4 (Sup-ft panel depicts the constructs in which amino acids were substituted from canine to
ts the constructs in which single amino acids were substituted from hBRC4 to cBRC4.
transfected into cells. The fusion proteins were detected by immunoblotting using
lane 2, hBRC4wt transfectant; lane 3, V1532I transfectant.
Fig. 3. Effect of the V1532F mutation of hBRC4 on its interaction with RAD51. (A) The left panel depicts the single amino acid substitution constructs V1532F, V1532I, T1526A,
and G1529R; the two tetrameric motifs in BRC4 that mediate its structural and functional interactions with cRAD51 [9] are underlined. The luciferase activity of hBRC4wt was
set at 100%. (B) Crystal structure of the hRAD51–hBRC4 complex (PDB ID: 1N0W). The solvent-accessible surface of RAD51 is shown in transparent dark green except M210
(light blue), and the BRC4 peptide is depicted as a gold ribbon. The residues of hBRC4wt are highlighted in purple (i.e., F1526, V1532, K1533, A1535, F1546, and D1547). The
V1532 substituted to Ile or Phe residues in the mutant BRC4 (V1532I or V1532F) are indicated in blue and yellow, respectively. (C) The probability values of the substitutions
of amino acid residues on V1532 (Dunbrack backbone-dependent rotamer library). The contacts or clashes between the residue at position 1532 were calculated and are
depicted (D), (E), and (F). BRC4 and RAD51 are depicted by gold and pink ribbons, respectively. Solid green lines signify stable contacts and solid red lines represent clashes, as
determined by the UCSF Chimera software.
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Fig. 4. Overexpression of V1532I mutant interferes with RAD51–RAD51 interaction. (A) The schematic at the top illustrates the EGFP–BRC4 fusion product containing a BRC4
cDNA fragment translationally fused to an EGFP–nuclear localization signal cassette in a modiﬁed pEGFP-C1 plasmid, NLS-pEGFP/BRC4. The lower graph shows the strength
of the interference caused by the expression of EGFP, wild-type EGFP–human BRC4 (EGFP–hBRC4wt), and hBRC4 with the canine amino acid substitution (EGFP–V1532I,
V1532F, T1526A, and G1529R) on cRAD51–cRAD51 interaction by MTH. (B) Schematic of the ELISA assay used to detect BRC–RAD51 interaction and its disruption by soluble
peptides. (C) In a competitive ELISA assay, the V1532I peptide inhibited the solid-phase BRC4 and human RAD51 interaction the more strongly than 4BRC4wt; however the
substitution of V1532F did not reconstitute the inhibitory behavior as much as hBRC4wt. Values are expressed as the mean (SE) absorbance at 490 nm for triplicate data sets
normalized to the positive control without a soluble inhibitor.
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of RAD51 binding.
3.4. Molecular mimicry of V1532I enhances the interference activity of
both RAD51–RAD51 and BRC4–RAD51 interactions to a greater extent
than that of hBRC4wt
To measure the strength of interference in RAD51–RAD51 inter-
action, interference constructs were added to the MTH assay.
V1532I inhibited cRAD51–cRAD51 interaction more signiﬁcantly
than hBRC4wt in a dose-dependent manner (Fig. 4A). On the other
hand, the BRC4mutants that exhibited very weak interactions with
RAD51 (i.e., V1532F, T1526A, and G1529R) did not inhibit cRAD51–
cRAD51 interaction (Fig. 4A). To verify the cell biological methods
used, we performed another in vitro assay: competitive ELISA
(Fig. 4B). Themutant peptides containing substitutionV1532I inhib-
ited the interaction between plate-coated BRC4 and hRAD51 more
strongly thanhBRC4wtpeptide. In contrast, theV1532Fmutantpep-
tide failed to competitively inhibit hRAD51–BRC4 interaction in the
ELISA assay (Fig. 4C). In addition, to determine the functional impor-
tance of the V1532I substitution in the interaction between BRC4
and endogenous RAD51, we performed a RAD51 focus assay
[24,25]. The RAD51 foci were more reduced by V1532I transfection
than hBRC4wt transfection (Supplementary Fig. 2A and B).
4. Discussion
This study used structural, cell biological, biochemical, and
comparative analyses to investigate the effects of reciprocal amino
acid substitutions on the interactions of human and canine BRC4with RAD51. Although the structures of mammalian RAD51–
BRC4 complexes—except that of humans—have not been clariﬁed,
RAD51 exhibits very high homology between mammals. For exam-
ple, canine and human RAD51 differ by only three amino acids out
of 339. Furthermore, these different residues are not located at an
important position on the RAD51–BRC4 binding surface [10,14].
Therefore, referring to the crystal structure of the human
RAD51–BRC4 complex is useful for analyzing the interaction be-
tween RAD51 and BRC4 in other mammals. The functional analysis
of BRCA2 revealed that canine and feline BRC4 interact more
strongly with cRAD51 than human BRC4. Two human BRC4 tetra-
meric motifs, namely 1524-FHTA-1527 and 1545-LFDE-1548, were
recently reported to be accommodated in the binding pockets of
RAD51 and are therefore essential for the interaction with the
RAD51 recombinase [9]. An efﬁcient chimera peptide of BRC
repeats was recently constructed in an attempt to improve the
anticancer properties of RAD51 inhibitors by selecting the best
amino acid residue at each binding position of the BRC repeats
[19]. However, V1532, which was identiﬁed in this study, had
not been identiﬁed previously as an important residue for binding
with RAD51. The single amino acid substitution of Val 1532 to Ile
in BRC4, which is speciﬁcally conserved in Carnivora and differs
by only one methyl group, remarkably enhanced the interaction
between BRC4 and RAD51. Crystallographic analysis revealed that
V1532 exists in the interacting interface of the BRC4–RAD51 com-
plex and that this interface of BRC4 mimics the oligomerization
motif of RAD51 [10,26,27]. Structural analysis of the substitution
of V1532I using the UCSF Chimera program validated the direct
interactions of V1532 and I1532 with M210 of RAD51 [10] and re-
vealed an additional contact between I1532 and A190. These re-
1776 K. Ochiai et al. / FEBS Letters 585 (2011) 1771–1777sults indicate enhanced interaction between V1532I and RAD51 as
shown by the increase in the number of contacts with the amino
acids of RAD51.
In this study, we investigated the interaction between BRC4
mutant and RAD51 by using modiﬁed MTH, competitive ELISA,
and RAD51 focus assays. EGFP–V1532I interfered with RAD51–
RAD51 interaction more strongly than EGFP–hBRC4wt. This result
suggests that the V1532I substitution in BRC4 may potentiate the
inhibition of RAD51 oligomerization by occupying hydrophobic
pockets that would normally be occupied by an adjacent RAD51
monomer in a ﬁlament [2,28]. Similarly, soluble V1532I BRC4 pep-
tide inhibited the interaction between plate-coated BRC4 peptides
and hRAD51 more strongly than hBRC4wt peptide. In addition, the
RAD51 foci were readily formed in mock-transfected control cells
and to a much lesser extent in cells transfected with EGFP–
hBRC4wt or EGFP–V1532I. These data suggest that the strong
interaction between the V1532I mutant and endogenous RAD51
inhibits the formation of RAD51 nucleoﬁlaments in DSBs via
endogenous BRCA2. This study demonstrates for the ﬁrst time
the role of Val 1532 of BRCA2 in its interaction with RAD51.
In addition, this study revealed the impairment of the interac-
tion between the V1532F mutant of hBRC4 (V1532F) and RAD51,
which was identiﬁed from human breast cancer patients. Although
the risks of the V1532F single BRC missense mutation have not
been investigated, V1532F might play an important role in the
interaction between BRC repeats and RAD51. The structural analy-
sis using UCSF Chimera revealed that the V1532F mutation in-
duced some clashes against H1525 and T1526. These distortions
in BRC4 conformation seemed to have caused the decrease in
RAD51–BRC4 binding activity because these two amino acid resi-
dues are reported to be necessary for RAD51–BRC4 interaction
[9,19]. Previous structural analyses of cancer-associated mutations
affecting the BRC repeats revealed that weakening RAD51 afﬁnity
in one repeat is enough to increase breast cancer susceptibility
[10,29,30]. However, the restoration of BRCA2 function in BRCA2-
deﬁcient cells by the expression of the construct connecting a sin-
gle BRC repeat and the replication protein A large subunit, which
delivers RAD51 to single-stranded DNA [31], suggests that further
analysis is necessary to conﬁrm a causal relationship between this
mutation and breast cancer onset.
Although the effects of random or cancer-associated amino acid
substitutions in human BRC4 on the inhibition of RAD51 interac-
tions are reported [23,30], there are no reports about the effect
of amino acid substitutions among animal species. In this study,
we found that the V1532I substitution strengthens the interaction
with RAD51, whereas V1532F abolishes it; this indicates a novel,
critical role of V1532 in BRC4–RAD51 interaction. Our ﬁndings
from the comparative analysis of BRCA2 between animal species
might be important for elucidating the general mechanism of
DNA repair mediated by BRC repeats.
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